PLAINSBORO, N.J., Feb. 26, 2016 -- Integra LifeSciences Holdings Corporation (NASDAQ:IART) today announced that it will present at the following conference in March:
- At 4:00PM ET on Tuesday, March 1, 2016, Mr. Mark Augusti, President – Orthopedics & Tissue Technologies, will present at the Canaccord 11th Annual Musculoskeletal Conference in Orlando, FL. This presentation will not be webcast.
- At 2:15PM ET on Monday, March 7, 2016, Mr. Glenn Coleman, Chief Financial Officer, will present at the Raymond James & Associates’ 37th Annual Institutional Investors Conference in Orlando, FL. This presentation will not be webcast.
- At 4:50PM ET on Tuesday, March 15, 2016, Mr. Coleman, will present at the Barclays Global Healthcare Conference in Miami, FL. This presentation will be webcast.
Integra LifeSciences, a world leader in medical technology, is dedicated to limiting uncertainty for caregivers, so they can concentrate on providing the best patient care. Integra offers innovative solutions, including leading regenerative technologies, in specialty surgical solutions and orthopedics and tissue technologies. For more information, please visit www.integralife.com
Statements made at the upcoming conferences may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ from predicted results. Forward-looking factors that may be discussed include, but are not limited to, future financial performance, new product development, governmental approvals, market potential and resulting sales as well as potential therapeutic applications, and additional acquisitions. These risks and uncertainties include market conditions and other factors beyond the Company's control and the economic, competitive, governmental, technological and other factors identified under the heading "Risk Factors" included in item 1A of Integra's Annual Report on Form 10-K for the year ended December 31, 2014 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results. These forward-looking statements are made only as the date thereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.
Contacts: Integra LifeSciences Holdings Corporation Investor Relations: Angela Steinway (609) 936-2268 [email protected] Michael Beaulieu (609) 750-2827 [email protected]


Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S.
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio
Nvidia and Groq Strike Strategic AI Inference Licensing Deal
FDA Approves Mitapivat for Anemia in Thalassemia Patients
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 



